Purpose A comanipulator for assisting endorectal prostate biopsies is evaluated through a first-in-man clinical trial. This lightweight system, based on conventional robotic components, possesses six degrees of freedom. It uses three electric motors and three brakes. It features a free mode, where its low friction and inertia allow for natural manipulation of the probe and a locked mode, exhibiting both a very low stiffness and a high steady-state precision. Methods Clinical trials focusing on the free mode and the locked mode of the robot are presented. The objective was to evaluate the practical usability and performance of the robot during clinical procedures. A research protocol for a prospective randomized clinical trial has been designed. Its specific goal was to compare the accuracy of biopsies performed with and without the assistance of the comanipulator. Results The accuracy is compared between biopsies performed with and without the assistance of the comanipulator, across the 10 first patients included in the trial. Results show a statistically significant increase in the precision.
Introduction Prostate cancer
Prostate cancer (PCa) is the fourth leading cause of cancer death in the world. With more than 900,000 new cases of prostate cancer each year in the world [1] , PCa is one of the major public health problems, with growing incidence about one man in seven that will be diagnosed with PCa during his lifetime, but whose therapeutic responses are not adapted to its growth. It is widely accepted today that a majority of patients would benefit in new clinical strategies as active surveillance or focal treatment.
The diagnosis is based on different examinations. The digital rectal evaluation and the prostate-specific antigen rate are performed during the screening phase, while biopsy session is the only examination allowing to diagnose the cancer. It consists of sampling the prostate tissue using a biopsy needle. In 2013, more than 230,000 new prostate cancer cases have been detected in the USA, thanks to hundreds of thousands biopsy procedures [1] .
The good distribution of biopsies in the prostate is the key aspect of the procedure as it limits the risk not to detect an existing tumor and the risk to overestimate a tumor extend. During standard examination, the urologist has to construct a mental 3D volume of the prostate using the 2D cross section provided by the ultrasound image. This is rather challenging, due to the mobility and deformations experienced by the prostate when moving the probe or inserting the needle, or caused by the patient motions [13, 23] .
A major technical difficulty arises from the desired precision for the needle placement, which is typically a few mm [14, 22] .
Robotic devices to assist for prostate needle insertion
Precisely positioning needles in a prostate is of crucial importance in terms of public health. It is required both for prostate biopsies and for brachytherapy, which consists of inserting radioactive seeds through a needle across the prostate volume in order to irradiate the cancerous tissue. Robotic assistance to needle placement in the prostate has been the object of interest for the robotics community in the past years. A recent exhaustive overview of these systems can be found in [10] . Two criteria can be used to categorize these systems: -Needle insertion path: transrectal or transperineal -Images used for guidance: ultrasonic images or MRI Transperineal needle insertion [2, 6, 7, 10, 16, 17, 26, 27] involves, most of the time, a general anesthesia, which means more important risks and higher cost. It is mainly devoted to brachytherpy and not to biopsies, apart from [21] , where a transperineal access is proposed for biopsies.
Using an MRI, as proposed in [8, 12, 15, 21] , induces a cost increase which limits its adoption, in particular for biopsy procedures whose cost should be limited as it is a common diagnostic procedure.
To avoid limitation form both MRI imaging and transperineal access, our system uses ultrasound images and allows transrectal needle insertion, as proposed in [12, 20] .
Assistance for prostate needle insertion through comanipulation
A major difference in our approach with respect to all the above-cited systems lies in the fact that the robotic device, called Apollo, does not move autonomously. Rather, it is comanipulated.
The urologist and the robot both manipulate the probe. Thus, with Apollo, the probe positioning is left to the urologist. During the positioning phase, the robot, whose end-effector is attached to the probe, shall leave the probe motion as free as possible. This first function is called the free mode. Once the probe has been manually positioned, Apolloprovides a second function: the locked mode, during which the urologist has his/her hands free to perform the needle placement and the biopsy. Note that Apollooffers other advanced assistance functions, such as prostate-probe contact force enhancement [25] , or autonomous fine positioning based on 3D USI [18] . These functions were not used in the present clinical study.
Being used as a simple free-locked device in the present clinical study, Apollois comparable with the system Artemis commercialized by Eigen [5] . Two major differences between Apolloand Artemis can be noticed.
First, Artemis is to be registered to the patient as its remote center of motion (RCM, which is a fixed point through which the transducer axis is constrained to pass) needs to precisely coincide with patient's anus. This induces a specific and careful procedure for the arm installation. On the contrary, Apollo possesses six degrees of freedom which allows for rough positioning of the base, simply accounting for workspace (reach) constraints. Apollo's kinematics is detailed in "Apollo's kinematics" section.
Second, Artemis is not active. In other words, whenever the urologist locks the device with brakes and releases the transducer, one may observe a probe displacement due to the fact that the force balance has been changed. Only a very high stiffness of the arm can limit this deformation. Because the patient is awake and may move, this rigidity is not desirable. On the contrary, when set in locked mode, Apolloexhibits a low stiffness. Meanwhile, thanks to its actuators and its controller (see "Assistance function" section), it can reach with a high precision the locked position in spite of disturbances.
We hypothesize that this last characteristic is of high impact on the clinical practice as it improves precision. However, to our knowledge, there is no evaluation of the probe displacement when the locked mode is turned on with Artemis. The first-in-man trial reported in "Clinical trial" section aims at comparing the biopsy accuracy when per-formed with and without Apollo's assistance. A clinical research protocol for a prospective randomized clinical trial has been designed to evaluate, for the first time, on patients, this non-CE marked innovative medical device. A device called Urostation Touch ® provides ground truth measurements. Results for the 10 first patients (five with robot and five without) included in this study show an increase in the precision thanks to the robot.
Proposed system
In this section, the main characteristics of Apollo are presented. A more detailed description, together with an in vitro evaluation can be found in [19] .
Apollo's kinematics
As evidenced from clinical data in [24] , the required workspace for the probe main axis can be modeled by a cone, whose origin coincides with the anatomical entry point, and the angle is typically 60 • , see Apollois made of six pivot joints serially assembled according to a conventional anthropomorphic geometry: The three first joints form the shoulder and the elbow, while the wrist is composed of the three last joints, whose axes coincide at a point P, see Fig. 1 . The geometry is completely described by Table 1 according to Denavit and Hartenberg notation, [4] .
The last pivot axis is designed in such a way that it leaves an 8-cm-diameter cylindrical hole whose axis coincides with the rotational axis. An interface part is designed to adapt to any specific probe shape and to connect to the robot endeffector. This part is fixed on the probe and can be placed 
into the robot end-effector thanks to a mechanical connector involving magnets.
Actuation
In order to maintain a high transparency (low friction, low weight, low inertia) for the robot's free mode, while being able to maintain the biopsy target at a precise location despite unknown disturbances in the locked mode, a hybrid actuation system is chosen:
-For the three wrist joints, small electromagnetic brakes are installed (Kebco 01.P1.300). The control of the brakes is binary: The brakes are either locked (ON), which corresponds to the unpowered state, or free (OFF), which corresponds to powered state. -To be able to compensate for the possible displacements due to external forces, electric motors (Maxon RE35) are mounted on the three first joints.
Furthermore, to increase transparency in the free mode:
-the motors are placed near the robot base, in such a way that their mass does not significantly affect the robot's inertia. -a cable transmission is used to limit joint friction.
-load springs are mounted on joints 2 and 3 to compensate for the robot weight.
The robot has been fabricated by Haption, a French company that commercializes high forces haptic interfaces [9] .
Assistance function
When the urologist wants to move the probe, the robot, whose end-effector is attached to the probe, shall leave the probe motion as free as possible. This first function is called the free mode. On the contrary, once the probe has been positioned, the urologist can switch to the locked mode.
The robot links weight is balanced by counterweights and springs in such a way that there is no need for compensation of the robot weight by the actuators. However, to ease the comanipulation, a gravity compensation is running to compensate for the weight of the probe.
During the free mode, brakes are OFF and nothing else but gravity compensation needs to be controlled as the robot was designed to ensure high transparency and reversibility, see Fig. 2 .
For the locked mode, a controller was developed to obtain simultaneously low stiffness and high precision. An inner loop compensates for gravity and emulates a spring between actual and desired locations. An external integrator is added to ensure precise positioning, see Fig. 3 . This integrator is saturated to avoid windup.
As demonstrated in [19] , even though the inner loop spring exhibits a low stiffness, this system allows to compensate for displacements that occur when the urologist releases the probe, within a few seconds.
Clinical trial
Following the successful in vitro and in cadavero experiments [19] , a clinical trial focusing on the free mode and the locked mode of the robot was prepared. The objectives are to evaluate the practical usability and performance of the robot on patients, with a main objective focused on the accuracy of biopsies performed with and without the assistance of the medical device Apollo.
An exhaustive risk analysis was performed to identify and control potential risks for patients and users. Furthermore, the robotic system was improved to comply with the applicable norms for medical devices, in particular the norms for basic safety of medical electrical equipment (EN 60601-1) and for medical software life cycle process (IEC 62304).
A clinical research protocol has been designed as a prospective randomized clinical trial, with respect to the scientific state of the art and the current regulatory frame related to clinical evaluation with non-CE marked devices. The sponsor is the Grenoble University Hospital, and the clinical trial has been authorized by the relevant French regulatory bodies: Agence Nationale du Médicament et des Produits de Santé (ANSM), the ethical comitee (Comité de Protection des Personnes Sud-Est V, CPP), and the Commission Nationale de l'Informatique et des Libertés (CNIL). The authorization number is NCT 02132975.
Twenty patients were included in this proof-of-concept study. The first patient (without robot) was included in November 2014, after obtaining the permissions to conduct the trial by all legal authorities, making it possible to perform the first intervention with robotic assistance in march 2015. Figure 4 shows the overall system installation in the operating room.
Protocol

General installation
In order to monitor the adequate positioning of the probe, the urologist was using a Urostation Touch ® , produced by the company Koelis (La Tronche, France), [11] . This system, which is approved for clinical use, is connected to a 3D ultrasound machine (Samsung V20). It is a mobile platform integrating several applications to assist prostate biopsy procedures with 3D imaging and intraoperative image fusion capabilities, within the usual clinical routine.
Urostation Touch ® connects to an ultrasound scanner equipped with a 3D endocavitary probe. It receives, stores, and processes 3D Dicom images of the prostate as the physician performs the biopsy procedure. It combines full 3D TRUS and automatic organ-based tracking [3] to create and visualize in real time the 3D mapping of biopsy samples, see The urologist records a 3D US image which is registered to the reference 3D image. Knowing the displacement computed by the registration algorithm, the Urostation Touch ® displays the expected location of the biopsy needle.
Scenario
For the robotized procedures, the robot is installed in the operating room before the biopsy session starts, see Fig. 6 .
The patient lies on left-lateral decubitus position. The robot (when used) is installed on patient's bed, behind his legs and the urologist connects the probe to the robot. An endorectal ultrasound probe fitted with a needle guide is inserted in the patient rectum Fig. 7 left. A local anesthesia is then preformed.
First, the probe is inserted into the patient's rectum (either manually or, for patients with robot, in the free mode). Immediately after introducing the probe, the urologist records a reference 3D US image. This reference image is displayed on a screen interface.
Then, the urologist moves the probe toward a first desired biopsy site. To this aim, he/she uses the real-time 2D US image and mental reconstruction of the anatomical geometry.
When the urologist thinks that the probe position is satisfactory for the biopsy, he/she makes a 3D US acquisition to visualize the "virtual biopsy." When the virtual biopsy is satisfactory (i.e., the currently targeted site as displayed in the 3D reference image is adequate), the urologist performs the biopsy and finally acquires a new 3D US image. In other words, for each biopsy, both the intended location and the effective location are recorded.
When done, the urologist can proceed to the next biopsy and repeat the above procedure until all the biopsies have been done. During the trial, the urologist had to position the probe at 12 different locations, according to the conventional sextant scheme (see Fig. 7, up-left) . This scheme is a general guideline used by the urologist but is not converted to exact target locations visualized in the reference 3D images.
The urologist also had to perform three supplementary biopsies targeted toward one suspicious lesion observed in MRI data (presenting a suspicious lesion from a preoperative MRI examination was indeed a criterion for inclusion in the For a given biopsy site, when the robot is not used, the urologist needs to manually maintain the probe from the beginning of the first 3D acquisition (virtual biopsy) the end of the second 3D acquisition (real biopsy). This corresponds to the current practice in clinical routine when using the Urostation Touch ® . On the contrary, when using the robot, the urologist selects the locked mode at the beginning of the first acquisition. He/she switches back to the free mode after the end of the second acquisition, when moving the probe toward the next biopsy location.
We hypothesize that the robot can minimize the displacement that occurs between the virtual biopsy (intended location) and the real biopsy (effective location). This is what was measured during the trial.
Results
The overall clinical study included 20 patients and three different urologists with various levels of expertise. We present here a first statistical analysis performed for the 10 first patients. Among them, two patients (patient 1 with robot and patient 8 without robot) were discharged from the study: The first one because of a needle guide material problem and the second one because he did not stop his anticoagulant treatment. The following data are thus given for eight patients (four with robot and four without robot). Patient clinical characteristics are given in Table 2 .
Hereafter, the quantitative parameters are described using mediane, 25th and 75th percentiles. The qualitative indicators are expressed as number and percentage. Due to the small number of patient, a nonparametric Mann-WhitneyWilcoxon test has been chosen.
Main criterion: distance between virtual and real biopsies
The main criterion analyzed is the distance between the virtual (desired) biopsy and the real one. A typical 3D map for the biopsies, as computed by the Urostation Touch ® for a given patient, is shown in Fig. 8 The results are given for the eight patients in Table 3 . The statistics for the median distance per patient (across 15 biopsies) are given in Table 4 . The median distance between virtual and real biopsies per patient is lower thanks to the robot (−0.77 mm = −46 %) with a statistical significance ( p = 0.029 < 0.05).
Secondary criteria
Several other criteria were defined in order to evaluate the impact of the use of the robot on the clinical practice.
The complete duration of the procedure (from the beginning of the installation to the patient's exit) was 33 min without robot and 41 min with the robot (median values across the patients). This 8-min (25 %) increase was due to installation of the robot prior to the patient arrival in the room, as well as to the time spent to show the robot and its control modes to the patient. This difference is not statistically significant ( p = 0.057 > 0.05) at this stage of the study.
Another secondary criterion was the possibility to explore the overall prostate with the robot. For all the four patients, it has been observed that the urologist was not disturbed by any workspace limitation of the robot.
Some qualitative results were also obtained through questionnaires to the urologist and to the patient after the procedure with robot. Urologists were asked about resistance felt during the free mode. They had to choose their answer between none, slight, moderate, or high. The urologists declared feeling "no resistance" when using the robot in the free mode, except, for two sessions, for the rotation around the probe main axis (a moderate resistance was then reported). The robot was "compact" to their opinion (they had to choose between "no presence noticeable," "compact," "moderately," or "highly cumbersome").
Urologists judged "very useful" the locked mode (they had to choose between useless, comfortable, useful, or very useful).
Three patients said they were reassured thanks to the robot use, the fourth one declared it did not change his apprehension. They felt no differences or forces due to switch between free and locked mode.
Finally, only one complication occurred during these experiments: One patient presents a urinary retention. It was not due to the robot. For one patient, the robot reached the security force saturation level to maintain the probe, but this did not impact the clinical procedure as this level was deliberately set far below the real capacity of the robot.
Discussion
Through these experiments, we were able to validate the overall setup and procedure. We did not encounter any difficulty to perform the biopsies with the robot even with the rough positioning of the robot with respect to the patient.
Obviously, this study is a preliminary clinical validation. One cannot state about the clinical added value based on this experiment. To validate the assistance provided by the robot and its overall setup (workspace, forces of the robot), a larger protocol should be defined with more surgeons and more patients. Furthermore, several patient characteristics (age, prostate volume, suspected lesion size) seem to be significantly different between the two groups despite the randomized assignment. The effect of these differences was not evaluated because of the small number of patients included in the study. This should be investigated through a clinical study with more patients.
Conclusion
In this paper, we presented Apollo, a comanipulator for assisting endorectal prostate biopsies. This lightweight system, based on conventional robotic components, possesses six degrees of freedom. It features a free mode, where its low friction and inertia allows for natural manipulation of the probe and a locked mode, exhibiting both a very low stiffness and a high steady-state precision.
A first evaluation with 10 human patients has been reported. Its main objective was to compare the accuracy of biopsies performed with and without the assistance of the medical device Apollo. Results exhibit a statistically significant increase in the precision.
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